First Patient Dosed in Randomized Ph 2 Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy
“This study aims to contribute to a transformation currently taking place in rectal cancer treatment. For locally advanced rectal cancer, traditionally chemoradiation followed by radical surgery has been the standard of care, despite the significant morbidity associated with surgery. Following the promising published phase 1b data, the current study assesses whether AN0025 increases the likelihood of achieving a cCR, when added to TNT in the treatment of locally advanced rectal cancer. We are very excited to explore the potential of AN0025 to improve efficacy, minimize invasive surgery, and offer patients a viable alternative,” said Prof Simon Gollins, the consultant in clinical oncology at Shrewsbury and Telford Hospital NHS Trust.
Share:
More News
“Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing
“Our encouraging Phase 2 data for GRANITE in MSS-CRC continue to mature and demonstrate durable benefit over time. With two additional months of follow-up, relative progression-free survival has further improved in the analysis of all patients treated with GRANITE, and most notably, in those with a lower tumor burden at
“Patients in the EU with ROS1 -positive non-small cell lung cancer and NTRK -positive solid tumors face a great unmet need for new therapies that may improve their outcomes and address or delay the difficult issue of treatment resistance,” said Joseph Fiore, vice president, global program lead, repotrectinib, Bristol Myers
“The acquisition of Biotheus builds on our successful ongoing collaboration on BNT327/PM8002 and other investigational bispecific antibodies,” said Prof. Ugur Sahin, M.D., Ph.D., CEO and co-founder of BioNTech. “We believe that BNT327/PM8002 has the potential to set a new standard of care in multiple oncology indications, surpassing traditional checkpoint inhibitors.
